Liminal BioSciences, Inc.
(NASDAQ : LMNL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.23%242.741.5%$877.10m
MRNAModerna, Inc. 4.78%149.680.0%$809.23m
VRTXVertex Pharmaceuticals, Inc. 0.31%282.661.9%$481.31m
GILDGilead Sciences, Inc. -0.29%61.631.0%$474.01m
REGNRegeneron Pharmaceuticals, Inc. -0.37%588.922.6%$469.90m
NVAXNovavax, Inc. 10.62%56.8975.7%$440.83m
ILMNIllumina, Inc. 1.64%187.383.3%$341.36m
SNSSSunesis Pharmaceuticals, Inc. -2.58%3.780.7%$264.24m
BIIBBiogen, Inc. 1.24%206.471.8%$241.02m
BNTXBioNTech SE 4.52%155.840.0%$195.61m
CRSPCRISPR Therapeutics AG 2.73%62.430.6%$164.46m
BMRNBioMarin Pharmaceutical, Inc. 0.45%83.244.2%$116.70m
EXASEXACT Sciences Corp. 2.54%40.3917.7%$93.24m
IOVAIovance Biotherapeutics, Inc. 2.63%11.330.0%$90.42m
TECHBio-Techne Corp. 0.42%348.094.5%$89.99m

Company Profile

Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.